Storia in 4 fonti

A standing ovation for RevMed, and caution for Akeso

ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

fiercebiotech.com3 mesi fa

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this ye | This year’s meeting…

Leggi questa versione → originale

Timeline cronologica

venerdì 29 maggio 2026·statnews.com
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
sabato 30 maggio 2026·statnews.com
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

A standing ovation for RevMed, and caution for Akeso

Confronto fonti

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

Timeline cronologica

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A standing ovation for RevMed, and caution for Akeso

A turning point for pancreatic cancer patients

At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer